ABBV vs ATR

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

AptarGroup exhibits strong financial health with a Piotroski F-Score of 8/9, indicating robust fundamentals and consistent profitability. The company trades below its growth-based intrinsic value of $186.14 but at a premium to its Graham defensive value of $77.42, reflecting reasonable valuation given its earnings momentum. Despite solid ROE of 15.62% and low debt/equity of 0.46, insider selling and weak technical trend signal caution. Analysts recommend a 'buy' with a target price of $159.14, implying 26% upside, though recent price performance remains negative over the past year.